SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026
Jade Biosciences announced the first participant has been dosed in the company’s first-in-human Phase 1 clinical trial evaluating JADE201, an investigational half-life extended afucosylated anti-BAFF receptor monoclonal antibody designed for the treatment of autoimmune diseases. The milestone marks Jade’s entry into clinical development for its next-generation B cell-targeting program, with interim Phase 1 data in rheumatoid arthritis expected in 2027.
JADE201 is engineered to target the B cell activating factor receptor (BAFF-R) using a dual mechanism intended to enhance B cell depletion while enabling more convenient dosing. The company believes the therapy has the potential to become a differentiated treatment option across multiple autoimmune diseases supported by BAFF-R biology.
JADE201 Designed to Improve B Cell Depletion Durability
JADE201 was developed to address major limitations associated with currently available B cell-directed therapies, including incomplete depletion in tissues, resistance mechanisms, and inconvenient treatment schedules. The antibody incorporates afucosylation technology to enhance antibody-dependent cellular cytotoxicity while also blocking BAFF signaling pathways involved in autoimmune disease progression.
According to Jade Biosciences, the investigational therapy combines enhanced antibody effector function with extended receptor occupancy, aiming to deliver deeper and longer-lasting B cell suppression compared with first-generation therapies. The company stated that the design may support infrequent subcutaneous dosing, an important factor for chronic autoimmune disease management.
Advertisement
In preclinical studies, JADE201 demonstrated high-affinity binding to BAFF-R, dose-dependent receptor occupancy, and sustained B cell depletion in non-human primates. Researchers also observed an extended half-life profile, supporting the possibility of less frequent dosing in human patients.
Company executives highlighted the broad therapeutic opportunity linked to BAFF-R biology, particularly in diseases driven by abnormal B cell activation and autoantibody production.
Phase 1 Trial Begins in Rheumatoid Arthritis Patients
The ongoing first-in-human study is a randomized, placebo-controlled Phase 1 clinical trial evaluating single ascending doses of JADE201 in participants with rheumatoid arthritis (RA). The study is designed to assess the therapy’s safety, tolerability, pharmacokinetics, and pharmacodynamics during early-stage clinical development.
Key biomarkers being evaluated include BAFF-R occupancy, soluble BAFF levels, and detailed B cell profiling to better understand the biological activity and durability of the investigational antibody. Interim data expected in 2027 are anticipated to help Jade prioritize future autoimmune indications for expanded clinical development.
Rheumatoid arthritis remains one of the most common autoimmune diseases worldwide, characterized by chronic inflammation, progressive joint damage, and systemic complications. Although biologics targeting B cells and inflammatory cytokines have transformed treatment, many patients continue to experience incomplete responses or loss of efficacy over time, creating demand for improved therapeutic options.
Jade Expands Autoimmune Disease Pipeline
Jade Biosciences is focused on developing best-in-class therapies for autoimmune diseases with high unmet medical need. In addition to JADE201, the company’s lead candidate JADE101 is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) through targeting the cytokine APRIL, another important immune pathway associated with B cell biology.
The company’s broader pipeline also includes JADE301, an undisclosed antibody candidate currently under development. Jade Biosciences was launched using assets licensed from Paragon Therapeutics, an antibody discovery platform founded by Fairmount.
The initiation of the JADE201 Phase 1 trial represents an important clinical milestone for Jade as competition intensifies in the rapidly growing autoimmune biologics market. With increasing industry focus on next-generation B cell therapies featuring improved durability and convenience, JADE201 could emerge as a differentiated candidate if future clinical data confirm its preclinical promise.
Source: Jade Biosciences press release
